Æ÷·³ > Áõ±ÇÆ÷·³ ¡å¡ã
  • Áõ±ÇÆ÷·³
  • ÀçÅ×Å©Æ÷·³
  • º¸ÇèÆ÷·³
> ºÐ·ù
¡å¡ã
  • ÀϹÝ
  • Áú¹®
  • ½ÃȲºÐ¼®
  • Á¾¸ñºÐ¼®
  • ¸Å¸Å³ëÇÏ¿ì
  • ¸Å¸ÅÀÏÁö
  • ÆÄ»ý
  • Æݵå
  • ä±Ç
  • ´º½º

¾ËÅ׿ÀÁ¨ Çس³׿ä 40


https://cts.businesswire.com/ct/CT?...">
  • Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints - Merck.com
  • Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with chemotherapy in adults with metastatic non-small cell lung cancer Merck to discuss results from MK-3475A-D77 study with regulatory authorities worldwide Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck¡¯s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ¢ç , together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; ¡°subcutaneous pembrolizumab¡±), administered with chemotherapy versus intravenous (IV) KEYTRUDA administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell
https://www.merck.com/news/merck-an... 

 

´ç¿¬È÷ µÉ °Å¶ó »ý°¢Çß°í

´ëÇѹα¹ ¹ÙÀÌ¿À ¿ª»ç¿¡ ³²À» ±â¾÷À̶ó »ý°¢ÇÕ´Ï´Ù

¹°·Ð 30¿¡ ÀüºÎ ³õ¾ÆÁÖ¾úÁö¸¸...

ÆéÆ®·ÐÀÌ À̾ ÇØÁÖ±æ ¹Ù¶ø´Ï´Ù

 ±âºÐÀÌ ÁÁ³×¿ä

4 ÃßõÇϱ⠴ٸ¥ÀÇ°ß 0 |
¸ñ·Ïº¸±â ÄÚ¸àÆ®ÀÛ¼º ÄÚ¸àÆ®40
±×³É´Ãº¸ ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
³ª´Â7¤¿¼ö´Ù ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
sjfuejskd ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
³ª´Â7¤¿¼ö´Ù ´Ù¸¥ÀÇ°ß 0 Ãßõ 2
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
È«À¯°æ ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
³ª´Â7¤¿¼ö´Ù ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
¿ÀÀÌ~! ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
³ª´Â7¤¿¼ö´Ù ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
¸Å¿ä ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
³ª´Â7¤¿¼ö´Ù ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
Àüü ÄÚ¸àÆ® º¸±â ¡å

¿å¼³, »óó ÁÙ ¼ö ÀÖ´Â ¾ÇÇÃÀº »ï°¡ÁÖ¼¼¿ä.